Electronic Spectacles Versus Low Dose Atropine in Young Myopes
Condition(s) studied
Investigational drug(s) / intervention(s)
eSpectacle Clinical prototype (CP1) device: The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
0.01% atropine: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
Study summary
This is a bilateral, dispensing, masked, randomized clinical trial. Myopic children will be randomly assigned to one of the following: (1) Investigational clinical prototype (CP1) device without atropine, (2) Investigational CP1 device with daily instillation of 0.01% atropine, or (3) daily instillation of 0.01% atropine without use of the investigational CP1 device. Primary endpoint: Difference in the 12-month change of cycloplegic spherical refractive error and axial length between each of the three treatment groups.
Eligibility
Primary outcome measure(s)
- CSER — 12 months
Difference in the changes of cycloplegic spherical refractive error between each of the three treatment groups. - AL — 12 months
Difference in the changes of axial length between each of the three treatment groups.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CMU Hsinchu Hospital | Hsinchu | Taiwan | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06034379 on ClinicalTrials.gov ↗ ← All trials in Taiwan